TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A policy published by the Department of Health and Human Services directs the FDA not to take action against specialty pharmacies that compound six wellness peptides, including BPC-157, TB-500 and KPV. The peptides have not been approved by the FDA for safety and effectiveness, and people familiar with the policy’s development told the Associated Press that FDA drug staff opposed the change. HHS says the approach offers a controlled alternative to black-market products, but the agency’s authority to enforce the policy’s safety conditions is disputed.
The Department of Health and Human Services has published a policy directing the Food and Drug Administration not to take action against specialty pharmacies that compound and sell six wellness peptides, including BPC-157, TB-500 and KPV. The chemicals have not been FDA-approved as safe and effective, and six people familiar with the decision told the Associated Press that FDA drug staff opposed the change and had limited input.
The policy, posted online Wednesday, covers injectable peptides promoted for wellness purposes such as muscle building, injury healing and increased energy. Under existing FDA rules, the substances would otherwise be considered illegal drugs because they have not completed the agency’s review process for safety and effectiveness. The policy changes enforcement rather than granting the peptides FDA approval.
HHS said the policy is intended to give Americans a “more controlled alternative” to peptides sold online, which the agency described as black-market products often made with unscreened ingredients. The document says pharmacies are directed to use peptide ingredients from FDA-registered factories, verify purity and collect information on side effects. Former FDA official Peter Lurie said the FDA does not have legal authority to enforce those pharmacy requirements.
According to people familiar with the deliberations, HHS initially considered asking the FDA to issue a regulation adding the peptides to a list of substances considered safe for compounding. FDA officials raised safety concerns and would not support that approach, the people told the Associated Press. HHS instead adopted a policy directing the agency not to enforce certain rules. FDA staff ultimately provided technical assistance, including on proposed safety conditions, the report said.
A New Route to Peptide Sales
The policy could make certain peptides easier to obtain through licensed U.S. compounding pharmacies, even though the substances have not been approved as safe and effective medicines. That distinction matters: the change affects the FDA’s enforcement posture; it does not establish that the products work for the conditions for which they are promoted.
The decision also puts HHS’s stated goal of expanding patient choice alongside concerns about evidence, product quality and oversight. Lurie, who leads the Center for Science in the Public Interest, warned that patients could turn away from tested treatments. He said that if people are diverted from approved drugs to unproven products, “there will be more unnecessary pain and suffering.” That is his assessment, not a reported finding about outcomes under the new policy.
There is also a commercial stake. Major telehealth provider Hims & Hers has announced plans to offer wellness peptides after a policy change, and Wall Street analysts estimate the market could exceed $2 billion. The source report does not specify the assumptions or time period behind that estimate.
Products Worth Considering
Garmin Forerunner 55 GPS Running Smartwatch, Black
Philips Sonicare DiamondClean 9500 Electric Toothbrush with 3 Brush Heads – Black
Levoit Eleva 300X HEPA Air Purifier
As an affiliate, we earn on qualifying purchases.
How the Policy Took Shape
Health Secretary Robert F. Kennedy Jr. has publicly supported peptides, calling himself a “big fan” and previously saying he used BPC-157 for a muscle injury. The policy is part of a broader shift in health policy associated with his “Make America Healthy Again” movement. Supporters have praised the change: Lee Rosebush of the American Academy of Peptide Medicine called it “a huge step for patient and provider medical freedom” in an online post.
Peptides are chains of amino acids, and some occur naturally in the body. FDA-approved peptide-based medicines include semaglutide and tirzepatide, used for diabetes and weight loss. Those approvals do not apply to the six substances covered by this policy. The source report says the wellness peptides are promoted for a range of conditions, but they have not received FDA approval for those uses.
Compounding pharmacies make customized medications, and decisions about their regulation have generally rested with the FDA. Oversight has drawn particular attention since a 2012 fungal meningitis outbreak was linked to contaminated injections from a Massachusetts compounding pharmacy. Compounding has since grown into a multibillion-dollar industry, according to the report.
“The change “advances patient choice and freedom.””
— Robert F. Kennedy Jr., as quoted in the HHS policy document
Safety Rules and Legal Reach
The policy’s practical effect will depend on how pharmacies and the FDA apply it. The document directs compounders to follow conditions involving ingredient sources, purity checks and side-effect reporting, but Lurie questioned whether the FDA can enforce those requirements. The source report does not describe a legal ruling on the agency’s authority.
It is also unclear how many pharmacies will offer the substances, how widely patients will use them, or what evidence will emerge about adverse effects and benefits. The policy does not amount to FDA approval, and the available report does not establish that the listed peptides are safe or effective for the conditions for which they are marketed. The reported opposition from FDA staff is based on accounts from people familiar with confidential deliberations, who spoke anonymously to the Associated Press.
Implementation and FDA Oversight
The next developments will show how the FDA implements the direction not to take action and whether compounding pharmacies begin offering the six peptides under the stated conditions. The agency’s role in checking ingredient sourcing, purity and reported side effects may be a focus, particularly given the dispute over its authority to enforce those conditions.
HHS has not, in the source material, provided a timetable for implementation or published outcome data on the policy. Further detail about which pharmacies participate, how safety reports will be reviewed and whether the policy faces legal or regulatory challenges remains pending.
Key Questions
Does the policy approve these peptides as medicines?
No. The policy changes the FDA’s enforcement approach toward certain specialty pharmacies; it does not grant the peptides FDA approval for safety and effectiveness.
Which peptides are covered?
The report names BPC-157, TB-500 and KPV among the six wellness peptides. It does not identify all six in the supplied material.
What safety conditions does the policy describe?
Compounders are directed to use ingredients from FDA-registered factories, verify peptide purity and collect information about side effects. A former FDA official questioned whether the agency has legal authority to enforce those requirements.
Why did FDA staff reportedly object?
People familiar with the policy’s development told the Associated Press that FDA drug staff had major safety concerns and warned that the change could weaken efforts to keep unproven products off the market. The staff’s reported objections came from anonymous sources familiar with confidential deliberations.
Source: medpagetoday.com
